In addition, Pembrolizumab was the first IO agent to be approved as monotherapy of advanced NSCLC with PD-L1 expression ≥50% and recently with PD-L1 expression ≥1% [10]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.